Aimei Health Technology Co., Ltd.
AFJKDrugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 12, 2026
29dMarket Overview
Stock performance and key metrics
1 upcoming, 1 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
23-valent pneumococcal polysaccharide vaccine | Phase 3 | Pneumococcal Disease | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Aimei Health Technology Co., Ltd.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Aimei Health Technology Co., Ltd.'s (AFJK) pipeline across Phase 3. Its lead program is 23-valent pneumococcal polysaccharide vaccine (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Aimei Health Technology Co., Ltd.'s next FDA catalyst?→
Aimei Health Technology Co., Ltd.'s (AFJK) next tracked catalyst is a Earnings expected August 12, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track AFJK biotech catalysts?→
Add AFJK to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Aimei Health Technology Co., Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.